Global Perspective on the Impact of the COVID-19 Pandemic on Rheumatology and Health Equity
Corresponding Author
Evelyn Hsieh
Yale School of Medicine, New Haven, Connecticut, and VA Connecticut Healthcare System, West Haven, Connecticut
Address correspondence via email to Evelyn Hsieh, MD, PhD, at [email protected], and Jinoos Yazdany, MD, MPH, at [email protected].
Search for more papers by this authorDzifa Dey
Korle-bu Teaching Hospital and the University of Ghana Medical School, Accra, Ghana
Search for more papers by this authorMengtao Li
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, and Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
Search for more papers by this authorPedro M. Machado
University College London, NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, Northwick Park Hospital, and London North West University Healthcare NHS Trust, London, UK
Search for more papers by this authorManuel F. Ugarte-Gil
Universidad Científica del Sur and Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Perú
Search for more papers by this authorCorresponding Author
Jinoos Yazdany
San Francisco General Hospital and University of California, San Francisco
Address correspondence via email to Evelyn Hsieh, MD, PhD, at [email protected], and Jinoos Yazdany, MD, MPH, at [email protected].
Search for more papers by this authorCorresponding Author
Evelyn Hsieh
Yale School of Medicine, New Haven, Connecticut, and VA Connecticut Healthcare System, West Haven, Connecticut
Address correspondence via email to Evelyn Hsieh, MD, PhD, at [email protected], and Jinoos Yazdany, MD, MPH, at [email protected].
Search for more papers by this authorDzifa Dey
Korle-bu Teaching Hospital and the University of Ghana Medical School, Accra, Ghana
Search for more papers by this authorMengtao Li
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, and Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
Search for more papers by this authorPedro M. Machado
University College London, NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, Northwick Park Hospital, and London North West University Healthcare NHS Trust, London, UK
Search for more papers by this authorManuel F. Ugarte-Gil
Universidad Científica del Sur and Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Perú
Search for more papers by this authorCorresponding Author
Jinoos Yazdany
San Francisco General Hospital and University of California, San Francisco
Address correspondence via email to Evelyn Hsieh, MD, PhD, at [email protected], and Jinoos Yazdany, MD, MPH, at [email protected].
Search for more papers by this authorAuthor disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/acr.25169.
Abstract
Although the public health emergency associated with the COVID-19 pandemic has ended, challenges remain, especially for individuals with rheumatic diseases. We aimed to assess the historical and ongoing effects of COVID-19 on individuals with rheumatic diseases and rheumatology practices globally, with specific attention to vulnerable communities and lessons learned. We reviewed literature from several countries and regions, including Africa, Australia and New Zealand, China, Europe, Latin America, and the US. In this review, we summarize literature that not only examines the impact of the pandemic on individuals with rheumatic diseases, but also research that reports the lasting changes to rheumatology patient care and practice, and health service use. Across countries, challenges faced by individuals with rheumatic diseases during the pandemic included disruptions in health care and medication supply shortages. These challenges were associated with worse disease and mental health outcomes in some studies, particularly among those who had social vulnerabilities defined by socioeconomic, race, or rurality. Moreover, rheumatology practice was impacted in all regions, with the uptake of telemedicine and changes in health care utilization. While many regions developed rapid guidelines to disseminate scientific information, misinformation and disinformation remained widespread. Finally, vaccine uptake among individuals with rheumatic diseases has been uneven across the world. As the acute phase of the pandemic wanes, ongoing efforts are needed to improve health care access, stabilize rheumatology drug supplies, improve public health communication, and implement evidence-based vaccination practices to reduce COVID-19 morbidity and mortality among individuals with rheumatic diseases.
Supporting Information
Filename | Description |
---|---|
acr25169-sup-0001-Disclosureform.pdf1.6 MB | Disclosure Form |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Mutapi F. How has COVID-19 hit Africa? Here's what the data tells us. World Economic Forum. 2021. URL: https://www.weforum.org/agenda/2021/10/why-africa-must-gather-its-own-data-to-tackle-the-pandemic/.
- 2Frimpong OB, Bihuzo RM, Commodore R. Wilson Center: Africa Program occasional paper. The COVID-19 pandemic in Africa: impact, responses, and lessons from Ghana, the Democratic Republic of the Congo, and Rwanda. URL: https://www.wilsoncenter.org/publication/covid-19-pandemic-africa-impact-responses-and-lessons-ghana-democratic-republic-congo.
- 3 OECD. COVID-19 and Africa: socio-economic implications and policy responses. 2020. URL: https://www.oecd.org/coronavirus/policy-responses/covid-19-and-africa-socio-economic-implications-and-policy-responses-96e1b282/.
- 4Ziadé N, El Kibbi L, Hmamouchi I, et al. Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: a study in 15 Arab countries. Int J Rheum Dis 2020; 23: 1550–7.
- 5Akintayo RO, Akpabio A, Kalla A, et al. COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic. Ann Rheum Dis 2021; 80:e100.
- 6Ntshalintshali SD, Geldenhuys EM, Moosajee F, et al. Access to chloroquine in patients with rheumatic and musculoskeletal diseases attending rheumatology outpatient clinics during the COVID-19 pandemic. S Afr Med J 2021; 111: 720–3.
- 7Zomalheto Z, Assogba C, Dossou-yovo H. Impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and disease-2019 (COVID-19) on the quality of life of rheumatoid arthritis patients in Benin. Egypt Rheumatol 2021; 43: 23–7.
- 8El Khouly RM, Elsabagh HM, Moawad AA, et al. Functional and mental health affection (depression, anxiety, stress) among Egyptian rheumatic diseases patients during COVID-19 pandemic. Eur Rev Med Pharmacol Sci 2022; 26: 4477–85.
- 9Ziadé N, Hmamouchi I, El Kibbi L, et al. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin Rheumatol 2020; 39: 3205–13.
- 10Akintayo RO, Akpabio AA, Kalla AA, et al. The impact of COVID-19 on rheumatology practice across Africa. Rheumatology (Oxford) 2021; 60: 392–8.
- 11Akintayo RO, Bahiri R, El Miedany Y, et al. African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol 2021; 40: 3445–54.
- 12Akintayo RO, Kalla A, Adebajo A. COVID-19 and African rheumatology: progress in adversity. Lancet Rheumatol 2020; 2: e732–4.
- 13 Africa Centres for Disease Control and Prevention. COVID 19 vaccine perceptions: a 15 country study. 2021. URL: https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study/.
- 14 National Institute for Communicable Diseases. COVID-19 vaccine rollout strategy FAQ. 2021. URL: https://www.nicd.ac.za/covid-19-vaccine-rollout-strategy-faq/.
- 15 National Primary Health Care Development Agency. Frequently asked questions. 2022. URL: https://nphcda.gov.ng/general-faqs/.
- 16Omran EA, Habashy RE, Ezz Elarab LA, et al. Anti-spike and neutralizing antibodies after two doses of COVID-19 Sinopharm/BIBP vaccine. Vaccines (Basel) 2022; 10: 1340.
- 17Ben Houmich T, Tali A, Debbagh F, et al. Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco). Int J Immunopathol Pharmacol 2022; 36:3946320221133697.
- 18Qi G, Wang H, Guo Y, et al. Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. Clin Rheumatol 2022; 41: 1899–910.
- 19Ye C, Cai S, Shen G, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 2020; 79: 1007–13.
- 20Zhao J, Pang R, Wu J, et al. Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences. Ann Rheum Dis 2021; 80:e63.
- 21Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2020; 2: e557–64.
- 22Zhao Y, Du J, Li Z, et al. It is time to improve the acceptance of COVID-19 vaccines among individuals with chronic diseases: a systematic review and meta-analysis [review]. J Med Virol 2023; 95:e28509.
- 23Tam LS, Tanaka Y, Handa R, et al. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis 2021; 24: 733–45.
- 24Su Z, Cheshmehzangi A, McDonnell D, et al. The advantages of the zero-COVID-19 strategy [review]. Int J Environ Res Public Health 2022; 19: 8767.
- 25Ahmed S, Grainger R, Santosa A, et al. APLAR recommendations on the practice of telemedicine in rheumatology. Int J Rheum Dis 2022; 25: 247–58.
- 26Zhang Y, Wang J, Zhao L, et al. Online management of rheumatoid arthritis during COVID-19 pandemic. Ann Rheum Dis 2021; 80:e4.
- 27Zeng H, Liu H, Liu Z, et al. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study. Hum Vaccin Immunother 2022; 18:2090176.
- 28Fan Y, Geng Y, Wang Y, et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis 2022; 81: 443–5.
- 29Yi Z, Yao Z, Xu D, et al. Attitudes toward COVID-19 vaccination: a survey of Chinese patients with rheumatic diseases. Vaccines (Basel) 2022; 10: 1604.
- 30Shen M, Dong L, Li M, et al. Recommendations on SARS-CoV-2 vaccination in adult patients with rheumatic diseases. Rheumatol Immunol Res 2021; 2: 213–6.
- 31 Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Rheumatology, et al. Expert recommendation on severe acute respiratory syndrome Coronavirus 2 vaccination in patients with chronic liver diseases, tuberculosis or rheumatoid diseases. Infectious Dis Immunity 2021; 1: 137–43.
10.1097/ID9.0000000000000021 Google Scholar
- 32Wilson N, Grout L, Summers JA, et al. Use of the elimination strategy in response to the COVID-19 pandemic: health and economic impacts for New Zealand relative to other OECD countries. medRxiv doi: https://doi.org/10.1101/2021.06.25.21259556. 2021. E-pub ahead of print.
10.1101/2021.06.25.21259556 Google Scholar
- 33Stobart A, Duckett S. Australia's response to COVID-19. Health Econ Policy Law 2022; 17: 95–106.
- 34Basseal JM, Bennett CM, Collignon P, et al. Key lessons from the COVID-19 public health response in Australia [review]. Lancet Reg Health West Pac 2023; 30:100616.
- 35Cai K, He J, Wong PK, et al. The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. Eur J Rheumatol 2020; 7 Suppl 2: S91–3.
- 36Oh Y, Hennessey A, Young L, et al. Evaluation of patient satisfaction for telehealth (telephone and video) in rheumatology outpatients during COVID-19 pandemic. Intern Med J 2022; 52: 559–65.
- 37Rischin A, Liew D, Black R, et al. Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. Intern Med J 2021; 51: 788–92.
- 38Jefferies S, French N, Gilkison C, et al. COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. Lancet Public Health 2020; 5: e612–23.
- 39Sonder GJ, Grey C, Anglemyer A, et al. The August 2020 COVID-19 outbreak in Aotearoa, New Zealand: delayed contact tracing for Pacific people contributes to widening health disparities. IJID Reg 2023; 6: 177–83.
- 40Mair J, Woolley M, Grainger R. Abrupt change to telephone follow-up clinics in a regional rheumatology service during COVID-19: analysis of treatment decisions. Intern Med J 2021; 51: 960–4.
- 41Zhu W, De Silva T, Eades L, et al. The impact of telerheumatology and COVID-19 on outcomes in a tertiary rheumatology service: a retrospective audit. Rheumatology (Oxford) 2021; 60: 3478–80.
- 42Roberts LJ, Lamont EG, Lim I, et al. Telerheumatology: an idea whose time has come. Intern Med J 2012; 42: 1072–8.
- 43Jhaveri D, Emeto TI, Alele FO, et al. Use of telemedicine for rheumatology practice in Queensland, Australia: experiences before and during the COVID-19 pandemic. Intern Med J 2022; 52: 1685–90.
- 44Lim I. Private practice and telerheumatology. In: C Peoples, editor. Telerheumatology: origins, current practice, and future directions. New York (NY): Springer Publishing; 2022. p. 281–9.
10.1007/978-3-031-00936-5_19 Google Scholar
- 45Garrido-Cumbrera M, Marzo-Ortega H, Christen L, et al. Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). RMD Open 2021; 7:e001546.
- 46Finch D, Tinson A. The continuing impact of COVID-19 on health and inequalities. The Health Foundation. 2022. URL: https://www.health.org.uk/publications/long-reads/the-continuing-impact-of-covid-19-on-health-and-inequalities.
- 47Dejaco C, Alunno A, Bijlsma JW, et al. Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Ann Rheum Dis 2021; 80: 518–26.
- 48Machado PM, Verschueren P, Grainger R, et al. Impact of COVID-19 pandemic on the management of patients with RA: a survey of rheumatologists in six European countries. Rheumatol Adv Pract 2022; 7:rkac108.
- 49Young K, Yeoh SA, Putman M, et al. The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatol Adv Pract 2022; 6:rkac001.
- 50Mitchell EJ, Ahmed K, Breeman S, et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials 2020; 21: 784.
- 51Mirza M, Siebert S, Pratt A, et al. Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology. Musculoskeletal Care 2022; 20: 209–13.
- 52Bijlsma JW, EULAR COVID-19 Task Force. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions. Ann Rheum Dis 2022;81: 786–8.
- 53Kroon FP, Najm A, Alunno A, et al. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis 2022; 81: 422–32.
- 54Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79: 851–8.
- 55Landewé RB, Kroon FP, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 2022; 81: 1628–39.
- 56 The Lancet. COVID-19 in Latin America: a humanitarian crisis [editorial]. Lancet 2020; 396: 1463.
- 57Elera-Fitzcarrald C, Ugarte-Gil MF, Alarcón GS. COVID-19 and its potential effect on patients with rheumatic diseases in Latin America. J Clin Rheumatol 2020; 26: 215–7.
- 58Isnardi CA, Roberts K, Saurit V, et al. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry. Clin Rheumatol 2023; 42: 563–78.
- 59Andrus JK, Evans-Gilbert T, Santos JI, et al. Perspectives on battling COVID-19 in countries of Latin America and the Caribbean. Am J Trop Med Hyg 2020; 103: 593–6.
- 60Busso M, Camacho J, Messina J, et al. Social protection and informality in Latin America during the COVID-19 pandemic. PLoS One 2021; 16:e0259050.
- 61Gamboa-Cárdenas RV, Barzola-Cerrón S, Toledo-Neira D, et al. Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin Rheumatol 2021; 40: 4725–34.
- 62Quintana R, Fernandez S, Guggia L, et al. Social networks as education strategies for indigenous patients with rheumatoid arthritis during COVID-19 pandemic. Are they useful? Clin Rheumatol 2022; 41: 3313–8.
- 63Fernández-Ávila DG, Barahona-Correa J, Romero-Alvernia D, et al. Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. Rheumatol Int 2022; 42: 41–9.
- 64Fernández-Ávila DG, Barahona-Correa J, Romero-Alvernia D, et al. Impact of COVID-19 pandemic on rheumatology practice in Latin America. J Rheumatol 2021; 48: 1616–22.
- 65Felten R, Dubois M, Ugarte-Gil MF, et al. Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. Rheumatology (Oxford) 2021; 60:SI68–76.
- 66Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World in Data. 2020. URL: https://ourworldindata.org/coronavirus.
- 67Santos-Moreno P, Rodríguez-Vargas GS, Casanova R, et al. Evaluation of a non-face-to-face multidisciplinary health care model in a population with rheumatoid arthritis vulnerable to COVID-19 in a health emergency situation. Healthcare (Basel) 2021; 9: 1744.
- 68George MD, Venkatachalam S, Banerjee S, et al. Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic. J Rheumatol 2021; 48: 603–7.
- 69George MD, Baker JF, Banerjee S, et al. Social distancing, health care disruptions, telemedicine use, and treatment interruption during the COVID-19 pandemic in patients with or without autoimmune rheumatic disease. ACR Open Rheumatol 2021; 3: 381–9.
- 70Maldonado D, Tu E, Mahmood SN, et al. Association of medication access difficulty and COVID-19-related distress with disease flares in rheumatology patients during the COVID-19 pandemic. Arthritis Care Res (Hoboken) 2021; 73: 1162–70.
- 71Dharia T, Venkatachalam S, Baker JF, et al. Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease. Arthritis Care Res (Hoboken) 2022; 74: 733–40.
- 72Mortezavi M, Lokineni S, Garg M, et al. Rheumatology patient satisfaction with telemedicine during the COVID-19 pandemic in the United States. J Patient Exp 2021; 8:23743735211008825.
10.1177/23743735211008825 Google Scholar
- 73Shaw YP, Hustek S, Nguyen N, et al. Rheumatic disease patient decision-making about COVID-19 vaccination: a qualitative analysis. BMC Rheumatol 2022; 6: 76.
- 74George MD, Danila MI, Watrous D, et al. Disruptions in rheumatology care and the rise of telehealth in response to the COVID-19 pandemic in a community practice-based network. Arthritis Care Res (Hoboken) 2021; 73: 1153–61.
- 75Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol 2021; 73: 374–80.
- 76Ugarte-Gil MF, Alarcón GS, Seet AM, et al. Association between race/ethnicity and COVID-19 outcomes in systemic lupus erythematosus patients from the United States: data from the COVID-19 Global Rheumatology Alliance. Arthritis Care Res (Hoboken) 2023; 75: 53–60.
- 77Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol 2022; 74: e21–36.
- 78Singh JA, Richards JS, Chang E, et al. Management of rheumatic diseases during the COVID-19 pandemic: a national Veterans Affairs survey of rheumatologists. Arthritis Care Res (Hoboken) 2021; 73: 998–1003.
- 79Li J, Ringold S, Curtis JR, et al. Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. Rheumatol Int 2021; 41: 1755–61.